azietomidate: a photolabel for gated ion channels; structure in first source
ID Source | ID |
---|---|
PubMed CID | 9971904 |
CHEMBL ID | 23812 |
SCHEMBL ID | 1044050 |
MeSH ID | M0448802 |
Synonym |
---|
2-(3-methyldiazirin-3-yl)ethyl 3-(1-phenylethyl)imidazole-4-carboxylate |
azietomidate |
CHEMBL23812 , |
gtpl5404 |
2-(3-methyl-3h-diazirin-3-yl)ethyl 1-(1-phenylethyl)-1h-imidazole-5-carboxylate |
[3h]azietomidate |
SCHEMBL1044050 |
Azietomidate is a photoreactive analog of the general anesthetic etomidate. It acts as a nicotinic acetylcholine receptor (nAChR) noncompetitive antagonist.
Excerpt | Reference | Relevance |
---|---|---|
"Azietomidate is a photoreactive analog of the general anesthetic etomidate that acts as a nicotinic acetylcholine receptor (nAChR) noncompetitive antagonist. " | ( Time-resolved photolabeling of the nicotinic acetylcholine receptor by [3H]azietomidate, an open-state inhibitor. Arevalo, E; Chiara, DC; Cohen, JB; Forman, SA; Hong, FH; Husain, SS; Miller, KW, 2009) | 2.03 |
Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 8 (88.89) | 29.6817 |
2010's | 1 (11.11) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.95) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 9 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |